Skip to main content
Equibles
VRCA logo

VRCA · Verrica Pharmaceuticals Inc.

Track VRCA — free Ask ALVIS about VRCA
$5.17 -0.28 (-5.06%) At close · Jul 24
Going-concern doubt — flagged May 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”
View the 10-Q filed May 12, 2026
Market Cap
$86.24M
Shares
17.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.44 Open$5.60 Day$5.44–5.68 52W$3.28–9.82 Avg vol 30d38K Short int316K · 1.8% float · 11.1d Short vol58% Last earningsMay 12, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 12

Up next

Next earnings call
Aug 13, 2026 Est · unconfirmed · in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 12, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 18.6 · elevated Equity put/call 0.79
      Technical
      price trend
      Strong Sell
      50 / 200-day cross Death cross
      Price vs 200-day avg −10%
      below
      Price vs 50-day avg −10%
      below
      RSI (14) 41
      neutral
      MACD trend Negative
      52-week position 33%
      mid-range
      Momentum
      relative strength
      Very Weak
      1-month return −7%
      trailing
      6-month return −25%
      trailing
      YTD return −35%
      this year
      Relative strength −31%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) Death cross
      50d $6 › 200d $6 — 200d above 50d
      Institutional flow Accumulating
      3 of 39 funds reported for Jun 30 · net +202 sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      1.84% of float · ▼ -2.7% MoM · 11.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      39 holders — mid 1-yr range
      Squeeze score 59
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +370%
      Y/Y
      EPS growth +89%
      Y/Y
      Free cash flow $-17.6M
      Balance sheet $5.2M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 95%
      annualized · 1-yr
      Max drawdown −53%
      past year
      ATR 8.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 2 · 0
      50 / 200-day cross
      Death cross Bearish
      Price vs 200-day avg
      −10% Bearish
      Price vs 50-day avg
      −10% Bearish
      RSI (14)
      41 Neutral
      MACD trend
      Negative Bearish
      52-week position
      33% Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) Death cross
      50d $6 › 200d $6 — 200d above 50d
      Institutional flow Accumulating
      3 of 39 funds reported for Jun 30 · net +202 sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      1.84% of float · ▼ -2.7% MoM · 11.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      39 holders — mid 1-yr range
      Price context
      position in its 52-week range
      52-wk low $3 Now $5 · 33% 52-wk high $10
      vs 200-day avg -10% vs 50-day avg -10% 50-day below 200-day death cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      non-GAAP net loss non-GAAP $8.8M Q1 2026 —
      Non-GAAP net loss per basic and diluted share non-GAAP $0.51 the quarter ended December 31, 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      VRCA
      Verrica Pharmaceuticals Inc.
      this stock
      		$86.24M -34.5% -43.3% — 1.8%
      ONC
      BeOne Medicines Ltd.
      		 $471.01B +7.6% +22179.2% 958.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $121.16B +4.4% +46.2% 28.3 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $68.78B -15.4% +20.8% 16.0 3.3%
      ARGX
      Argenx SE
      		 $57.44B +9.9% — — 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      40
      % held
      27.8%
      Reported
      3 of 39
      Top holder
      Caligan Partners LP
      Held Float
      View
      Held by Funds
      Fund positions
      13
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      315.8K
      Days to cover
      11.1d
      Change
      -8.9K sh
      View
      Short Volume
      Short vol %
      58%
      As of
      Jul 24, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.5K
      Value
      $17.0K
      As of
      Jun 29, 2026
      View
      Off-Exchange
      Off-exchange %
      39.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $35.6M
      Net income (FY)
      $-17.9M
      EPS diluted
      $-1.68
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 9, 2026
      This year
      6
      View
      Proposed Sales
      Value
      $94.3K
      Shares
      36.0K
      Filed
      Aug 26, 2024
      View
      Exempt Offerings
      Offering
      $50.0M
      Filed
      Dec 10, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      VRCA -2.2% -7.0% -24.6% -11.1% -34.5%
      SPY -1.7% +0.7% +6.4% -1.2% +8.3%
      vs SPY -0.5% -7.7% -30.9% -10.0% -42.8%
      Key facts CIK 1660334 CUSIP 92511W207 13F (30d) 3 filings 3 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)